Thalidomide-NH-C6-NH-Boc
≥95%
- Product Code: 63062
CAS:
2093536-13-9
| Molecular Weight: | 472.53 g./mol | Molecular Formula: | C₂₄H₃₂N₄O₆ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, sealed, dry |
Product Description:
Thalidomide-NH-C6-NH-Boc is a derivative of thalidomide, modified with a Boc-protected aminohexyl linker. This compound is primarily used in medicinal chemistry and drug development research. Its application lies in its potential as a versatile intermediate for synthesizing more complex molecules, particularly in the design of targeted therapies. The Boc group serves as a protective moiety, allowing for selective chemical reactions to be carried out on other parts of the molecule. This compound is often employed in the development of proteolysis-targeting chimeras (PROTACs), which are innovative therapeutic agents designed to degrade specific disease-causing proteins. Additionally, its thalidomide core enables binding to cereblon, a protein involved in the ubiquitin-proteasome system, making it valuable in cancer research and the treatment of conditions like multiple myeloma. Its structural features also make it useful in exploring immunomodulatory and anti-inflammatory properties in various experimental models.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.250 | 10-20 days | ฿27,000.00 |
+
-
|
Thalidomide-NH-C6-NH-Boc
Thalidomide-NH-C6-NH-Boc is a derivative of thalidomide, modified with a Boc-protected aminohexyl linker. This compound is primarily used in medicinal chemistry and drug development research. Its application lies in its potential as a versatile intermediate for synthesizing more complex molecules, particularly in the design of targeted therapies. The Boc group serves as a protective moiety, allowing for selective chemical reactions to be carried out on other parts of the molecule. This compound is often employed in the development of proteolysis-targeting chimeras (PROTACs), which are innovative therapeutic agents designed to degrade specific disease-causing proteins. Additionally, its thalidomide core enables binding to cereblon, a protein involved in the ubiquitin-proteasome system, making it valuable in cancer research and the treatment of conditions like multiple myeloma. Its structural features also make it useful in exploring immunomodulatory and anti-inflammatory properties in various experimental models.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :